Isomark, LLC

isomark has developed a patented, non-invasive technology that can be used to monitor personal health and disease states by measuring and analyzing isotopic biomarkers through exhaled co2 samples. isomark’s technology can rapidly measure a patented set of breath biomarkers for detecting the presence of infection in as little as two hours after onset. presently, 1.7 million hospital patients in the united states contract infections annually. more than 750,000 of those infections will lead to sepsis, resulting in more than 200,000 patient deaths and over $33 billion spent in treatment. in addition to its non-invasive nature, isomark’s technology also can provide near real-time results, in contrast to current diagnostic tests which require hours or days for laboratory analysis. this represents not only a significant health benefit to patients but also substantive cost savings to consumers, insurance companies, and healthcare providers.